Last reviewed · How we verify
18F-FTC-146
At a glance
| Generic name | 18F-FTC-146 |
|---|---|
| Also known as | FTC146 |
| Sponsor | Guido A. Davidzon, MD, SM |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Reliability of [18F]-FTC-146 Brain Uptake in Healthy Controls (PHASE1)
- PET/MRI in the Diagnosis of Pediatric Chronic Pain (PHASE1)
- PETMRI for Chronic Pain from Spinal or Peripheral Nerve Origin (PHASE1)
- 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma (PHASE2)
- PET/MRI in the Diagnosis of Chronic Pain (PHASE1)
- Novel Clinical Target in Fragile X Syndrome (PHASE1)
- [18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 18F-FTC-146 CI brief — competitive landscape report
- 18F-FTC-146 updates RSS · CI watch RSS
- Guido A. Davidzon, MD, SM portfolio CI